In the meantime, Wall Street is also worried about the company's Revlimid drug, which accounts for about two-third's of revenues. By 2022, it will lose its patent protection, resulting in competition from generic drug companies. For the most part, Celgene is in a race to overcome the likely reduction in revenues.